
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

September 25, 2013 (September 25, 2013)

HARRIS & HARRIS GROUP, INC.

(Exact name of registrant as specified in its charter)

New York
(State or other jurisdiction of
incorporation)

0-11576
(Commission File
Number)

13-3119827
(IRS Employer
Identification No.)

1450 Broadway
New York, New York 10018

(Address of principal executive offices and zip code)

(212) 582-0900

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

Harris & Harris Group, Inc. (the "Company") noted today an article in *The New York Times* discussing the purchase by Unilever, the consumer products giant, of large amounts of oil from Solazyme, Inc., a start-up company that bioengineers algae to produce oils, proteins and complex sugars. *The New York Times* article may be viewed at http://www.nytimes.com/2013/09/25/business/energy-environment/unilever-to-buy-oil-derived-from-algae-from-solazyme.html?_r=0. The Company is an investor in publicly traded Solazyme, Inc.

Item 9.01. Financial Statements and Exhibits.

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibits.

Exhibit No. Description

99.1 Press Release dated September 25, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 25, 2013

HARRIS & HARRIS GROUP, INC.

By: /s/ Daniel B. Wolfe

Daniel B. Wolfe

President

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release dated September 25, 2013

PRESS RELEASE

HARRIS & HARRIS GROUP, INC. ®
1450 BROADWAY, 24TH FLOOR
NEW YORK, NY 10018
TEL. NO. (212) 582-0900

FOR IMMEDIATE RELEASE

SEPTEMBER 25, 2013

CONTACT: DOUGLAS W. JAMISON

**Harris & Harris Group Notes Unilever's Purchase of
Algae-Produced Oil from Solazyme**

Harris & Harris Group, Inc. (NASDAQ: TINY), an early-stage, active investor in transformative companies, notes an article in *The New York Times* discussing the purchase by Unilever, the consumer products giant, of large amounts of oil from Solazyme, Inc., a start-up company that bioengineers algae to produce oils, proteins and complex sugars.

Unilever said it would use the oil for its personal care products, which include Dove and Brylcreem. The agreement, under which Unilever plans to buy roughly three million gallons of the algae-produced oil over 12 to 18 months starting early next year, is part of its aim to double the size of its business while reducing its overall environmental footprint. For Solazyme, the agreement represents an important step as it ramps up to commercial-scale production. Originally conceived as a fuel business, Solazyme has focused on making oils for products with higher profit margins like personal care, food and petrochemicals. The Unilever oil, developed in a five-year partnership with Solazyme, will be made at a plant it built in Brazil with Bunge, a leading agribusiness and food company. When fully operational, the plant could produce roughly 30 million gallons of oil a year. The article in *The New York Times* can be accessed at http://www.nytimes.com/2013/09/25/business/energy-environment/unilever-to-buy-oil-derived-from-algae-from-solazyme.html?_r=0.

Harris & Harris Group is an investor in publicly traded Solazyme, Inc., and was its first institutional investor in 2004.

Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com and on Facebook at www.facebook.com/harrisharrisvc.

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com, www.facebook.com and www.nytimes.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.
